{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Rottmann FA"],"pubmed_abstract":["<h4>Background</h4>Patients with heart failure frequently present with kidney dysfunction. Kidney function is relevant, as prognosis declines with reduced kidney function and potentially beneficial drugs like levosimendan are contraindicated for missing safety data.<h4>Materials and methods</h4>A single-center retrospective registry study was conducted including all patients receiving levosimendan on a medical intensive care unit between January 2010 and December 2019. Exclusion criteria were a follow-up less than 24 h or missing glomerular filtration rate (eGFR) before administration of levosimendan. The first course of treatment was evaluated. Patients were stratified by eGFR before drug administration and the primary endpoint was a composite of supraventricular-, ventricular tachycardia"],"journal":["Frontiers in cardiovascular medicine"],"pagination":["1027727"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9631470"],"repository":["biostudies-literature"],"pubmed_title":["Levosimendan in acute heart failure with severely reduced kidney function, a propensity score matched registry study."],"pmcid":["PMC9631470"],"pubmed_authors":["Staudacher DL","Bemtgen X","Breiden AK","Wengenmayer T","Supady A","Rottmann FA","Welte T"],"additional_accession":[]},"is_claimable":false,"name":"Levosimendan in acute heart failure with severely reduced kidney function, a propensity score matched registry study.","description":"<h4>Background</h4>Patients with heart failure frequently present with kidney dysfunction. Kidney function is relevant, as prognosis declines with reduced kidney function and potentially beneficial drugs like levosimendan are contraindicated for missing safety data.<h4>Materials and methods</h4>A single-center retrospective registry study was conducted including all patients receiving levosimendan on a medical intensive care unit between January 2010 and December 2019. Exclusion criteria were a follow-up less than 24 h or missing glomerular filtration rate (eGFR) before administration of levosimendan. The first course of treatment was evaluated. Patients were stratified by eGFR before drug administration and the primary endpoint was a composite of supraventricular-, ventricular tachycardia","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-21T16:50:28.424Z","creation":"2025-04-21T16:50:28.424Z"},"accession":"S-EPMC9631470","cross_references":{"pubmed":["36337866"],"doi":["10.3389/fcvm.2022.1027727"]}}